FGFR3 mutations in prostate cancer: association with low-grade tumors

Sílvia Hernández, Silvia de Muga, Laia Agell, +6

Modern Pathology

UrologyGenitourinary CancerMolecular OncologyFgfr3 MutationsProstatic Disease +2

Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas

Silvia de Muga, Sílvia Hernández, Laia Agell, +6

Modern Pathology

UrologyGenitourinary CancerMedicinePathologyMolecular Alterations +6

A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer

Laia Agell, Sílvia Hernández, Lara Nonell, +9

American Journal Of Pathology

Aggressive HistologicalGenitourinary CancerMedicine12-Gene Expression SignaturePathology +9

Association of <i>ERG</i> and <i>TMPRSS2‐ERG</i> with grade, stage, and prognosis of prostate cancer is dependent on their expression levels

Alba Font‐Tello, Núria Juanpere, Silvia de Muga, +7

The Prostate

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer

Núria Juanpere, Laia Agell, Marta Lorenzo, +8

Human Pathology

UrologyUrothelial Bladder CancerGenitourinary CancerPathologyMapk Pathway Activation +3

<scp>HER2</scp> as a target in invasive urothelial carcinoma

Joaquim Bellmunt, Lillian Werner, Aristotle Bamias, +17

Cancer Medicine

PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events

Laia Agell, Sílvia Hernández, Marta Salido, +8

Modern Pathology

UrologySignal TransductionSignaling PathwayCopy GainReceptor Tyrosine Kinase +8

KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations

Laia Agell, Sílvia Hernández, Silvia de Muga, +6

Modern Pathology

UrologyTumor HeterogeneityMedicinePathologyCancer Genomics +6

Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC

Roberto Martínez, Gustavo Tapia, Silvia de Muga, +10

OncoImmunology

Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients

Joana Vidal, Sergi Clavé, Silvia de Muga, +18

Journal of Thoracic Oncology

MedicineEpidemiology Of CancerPathologyBronchial NeoplasmCancer Prevention +4